Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
Ninna Hahn Tougaard(Steno Diabetes Centers), Peter Rossing(Steno Diabetes Centers), Carol Forsblom(University of Helsinki), Per‐Henrik Groop(University of Helsinki), Cristina Legido‐Quigley(Steno Diabetes Centers), Markku Lehto(University of Helsinki), Sohvi Hörkkö(University of Oulu), Andressa de Zawadzki(Steno Diabetes Centers), Elisabeth B. Stougaard(Steno Diabetes Centers), Ismo Mattila(Steno Diabetes Centers), Marie Frimodt‐Møller(Steno Diabetes Centers), Hanne Salmenkari(University of Helsinki), Tine W. Hansen(Steno Diabetes Centers)
Cited by 35
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k